Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 first in human clinical trial of nitric oxide for solid tumour

Next Previous
Trial Profile

Phase 1 first in human clinical trial of nitric oxide for solid tumour

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nitric oxide (Primary)
  • Indications Skin cancer; Solid tumours
  • Focus Adverse reactions; First in man; Proof of concept

Most Recent Events

  • 13 Feb 2026 According to a Beyond Air media release, Part A of the trial evaluating UNO therapy in 10 subjects with advanced, relapsed or refractory unresectable, primary or metastatic cutaneous and subcutaneous solid tumors at a dose of 25,000 ppm has been completed.
  • 13 Feb 2026 According to a Beyond Air media release, the trial to be presented at the AACR 2026 Annual Meeting in April.
  • 03 Nov 2023 According to a Beyond Cancer media release, additional results from this trial for UNO expected in 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top